References : Epilepsy.com/Professionals

WHO IS EPILEPSY.COM/PROFESSIONALS

DONATE

References

Author: V Bassi, M Kita, DS Feldman, and O Devinsky

1. Lance JW, Symposium Synopsis. In RG Feldman, RR Young, WP Koella (eds), Spasticity: Disordered Motor Control. Chicago: Yearbook Medical, 1980;485–494.

2. Young RR. Spasticity: a review. Neurology 1994;44[Suppl 9]:S12–S20.

3. Carpenter MB. Core Text of Neuroanatomy (4th ed). Baltimore: Williams & Wilkins, 1991;101–110.

4. Curtis BA, Jacobson S, Marcus EM. An Introduction to the Neurosciences. Philadelphia: Saunders, 1972;200–206.

5. Meythaler JM, Tuel SM, Cross LL. Spinal cord seizures: a possible cause of isolated myoclonic activity in traumatic spinal cord injury: a case report. Paraplegia 1991;29(8):557–560.

6. Cherrick AA, Ellenberg M. Spinal cord seizures in transverse myelopathy: report of two cases. Arch Phys Med Rehabil 1986;67(2):129–131.

7. Haghighi SS, Clapper A, Johnson GC, et al. Effect of 4-aminopyridine and single dose methylprednisolone on functional recovery after a chronic spinal cord injury. Spinal Cord 1998;36(1):6–12.

8. Albright AL. Spasticity and movement disorders in cerebral palsy. J Child Neurol 1996;11[Suppl 1]:S1–S4.

9. Kyllerman M, Baber B, Billie B. Dyskinetic cerebral palsy. Acta Paediatr Scand 1982;71:543–550.

10. Kuben KCK, Leviton A. Cerebral palsy. N Engl J Med 1994;330:188–195.

11. The Australian and New Zealand Perinatal Societies. The origins of cerebral palsy—a consensus statement. Med J Aust 1995;162:85–90.

12. Bax M, Nelson KB. Birth asphyxia: a statement. Dev Med Child Neurol 1993;35:1022–1024.

13. Sugimoto T, Woo M, Nishida N. When do brain abnormalities in CP occur? An MRI study. Dev Med Child Neurol 1995;13:67–78.

14. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In CD Marsden, S Fahn (eds), Movement Disorders 2. London: Butterworth, 1987;332–358.

15. Albright AL. Cerebral palsy. Pediatr Ann 1997;26:592–598.

16. Aicardi J. Epilepsy in brain-injured children. Dev Med Child Neurol 1990;32:191–202.

17. Hadjipanayis A, Hadjichristodoulou C, Youroukos S. Epilepsy in patients with cerebral palsy. Dev Med Child Neurol 1997;39:659–663.

18. Okumura A, Hayakawa F, Kato T, et al. Epilepsy in patients with spastic cerebral palsy: correlation with MRI findings at 5 years of age. Brain Dev 1999;21:540–543.

19. Aksu F. Nature and prognosis of seizures in patients with cerebral palsy. Dev Med Child Neurol 1990;32:661–668.

20. Bormann J. Electrophysiology of GABA(A) and GABA(B) receptor subtypes. Trends Neurosci 1988;11:112–116.

21. Davidoff RA. Antispasticity drugs: mechanism of action. Ann Neurol 1985;17:107–117.

22. van Hemet JCJ. A double-blind comparison of baclofen and placebo in patients with spasticity of cerebral origin. In RG Feldman, RR Young, WP Koella (eds), Spasticity: Disordered Motor Control. Chicago: Yearbook Medical, 1980.

23. Mariko K, Goodkin DE. Drugs used to treat spasticity. Drugs 2000;59(3):487–495.

24. Jerusalem F. A double-blind study on the antispastic action of beta-(4-chlorophenyl)-gamma-amino butyric acid in multiple sclerosis. Nervenarzt 1968;39:515.

25. Jones RF, Burke D, Morasszeky JE, Gillies DJ. A new agent for the control of spasticity. J Neurol Neurosurg Psychiatry 1970;33:464–468.

26. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. Br Med J 1971;4:15–17.

27. Pedersen E, Arlien-Soborg P, Mai J, The mode of action of the BAGA derivative baclofen in human spasticity. Acta Neurol Scand 1974;50:665–680.

28. Milanov IG. Mechanisms of baclofen action on spasticity. Acta Neurol Scand 1992;85:305–310.

29. Rivas DA, Chancellor MB, Hill K, Freedman MK. Neurological manifestations of baclofen withdrawal. J Urol 1993;150:1903–1905.

30. Kofler M, Leis A. Prolonged seizure activity after baclofen withdrawal. Neurology 1992;42:697–680.

31. Costa E, Guidotti A. Molecular mechanisms in the receptor action of the benzodiazepines. Annu Rev Toxicol 1979;19:531–545.

32. Schwarz M, Turski L, Janiszewski W, Sontag K-H. Is the muscle relaxant effect of diazepam in spastic mutant rats mediated through GABA-independent benzodiazepine receptors? Neurosci Lett 1983;36:175–180.

33. Pedersen E. Clinical assessment and pharmacologic therapy of spasticity. Arch Phys Med Rehabil 1974;55:344–354.

34. Kendall PH. The use of diazepam in hemiplegia. Ann Phys Med 1964;7:225–228.

35. Neill RW. Diazepam in the relief of muscle spasm resulting from spinal-cord lesions. Ann Phys Med 1964;[Suppl]:33–38.

36. Nathan PW. The action of diazepam in neurological disorders with excessive motor activity. J Neurol Sci 1970;10:33–50.

37. Corbett M, Frankel HL, Michaelis L. A double blind cross-over trial of Valium in the treatment of spasticity. Paraplegia 1972;10:19–22.

38. From A, Heltberg A. A double-blind trial with baclofen and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975;51:158–166.

39. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica 1987;4(5):278–284.

40. Cartlidge NEF, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974;23:17–24.

41. Mitchell G. Update on multiple sclerosis therapy. Med Clin North Am 1993;77:231–249.

42. Coward DM. Selective muscle relaxant properties of tizanidine and an examination of its mode of action. Triangle 1981;20:151–158.

43. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl- amino)-2,1,3-benzothiadazole (DS 103 282). Br J Pharmacol 1982;76:473–481.

44. Newman PM, Nogues M, Newman PK, et al. Tizani- dine in the treatment of spasticity. Eur J Clin Pharmacol 1982;23:31–35.

45. Delwaide PJ. Electrophysiological testing of spastic patients: its potential usefulness and limitations. In PJ Delwaide, RR Young (eds), Clinical Neurophysiology in Spasticity. Amsterdam: Elsevier, 1985;185–203.

46. The United Kingdom Tizanidine Study Group. A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused my multiple sclerosis. Neurology 1994;44[Suppl 9]:70–79.

47. Lapierre Y, Bouchard S, Tansey C, et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987;14:513–517.

48. Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994;[Suppl 9]:S44–S52.

49. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand 1994;89:274–279.

50. Bass B, Weinshenker B, Rice GPA, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Sci 1988;15(1):15–19.

51. Stein R, Nordal HJ, Oftendal SI, Slebetto M. The treatment of spasticity in multiple sclerosis: a double- blind clinical trial of a new anti-spasticity drug tizani- dine compared with baclofen. Acta Neurol Scand 1987;75:190–194.

52. Smolenski C, Muff S, Smolenski-Kauts S. A double- blind comparative trial of a new muscle-relaxant, tizanidine (DS102-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981;7(6):374–383.

53. Hoorgstraten MC, van der Ploeg RJO, van der Burg W, et al. Tizanidine versus baclofen in the treatment of multiple sclerosis patients. Acta Neurol Scand 1988;77:224–230.

54. Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988;10(10):699–708.

55. Pagano MA, Ferreiro ME, Herskovits E. Comparative study of tizanidine and baclofen in patients with chronic spasticity. Rev Neurol Argent 1988;14(4):268–276.

56. Rinne UK. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res 1980;28(6):827–836.

57. Bes A, Eyssette M, Pierrot-Deseilligny E, et al. A multi-centre, double-blind trial of tizanidine, a new anti-spastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988;10:709–718.

58. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989;4:296–301.

59. Dall JT, Harmon RL, Quinn CM. Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Brain Inj 1996;10(6):453–458.

60. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988;69(3):193–194.

61. Herman R, Mayer N, Mecomber SA. Clinical pharmaco-physiology of dantrolene sodium. Am J Phys Med 1972;51:296–311.

62. Ellis KO, Carpenter JF. Mechanisms of control of skeletal muscle contraction by dantrolene sodium. Arch Phys Med Rehabil 1974;55:362–369.

63. Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13:3–23.

64. Whyte J, Robinson KM. Pharmacologic management. In M Glenn, J Whyte (eds), The Practical Management of Spasticity in Children and Adults. Philadelphia: Lea & Febiger, 1990.

65. Monster AW, Tamai Y, McHenry J. Dantrolene sodium in spasticity. Acta Neurol Scand 1979;59:309–316.

66. Gelenberg AJ, Poskanzer DC. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973;23:1313–1315.

67. Tolosa ES, Soll RW, Loewenson R. Treatment of spasticity in multiple sclerosis with dantrolene. JAMA 1975;233(10):1046.

68. Katrak PH, Cole A, Poulos CJ, McCAuley JCK. Objective assessment of spasticity, strength and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil 1992;73:4–9.

69. Schmidt RT, Lee RH, Spehlman R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976;39:350–356.

70. Nogen AG. Medical treatment for spasticity in children with cerebral palsy. Childs Brain 1976;2:304–308.

71. Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia 1974;12:170–174.

72. The US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994;18(1):67–73.

73. Fromm GH. Gabapentin. Epilepsia 1995;36[Suppl 5]:S77–S80.

74. McLean MJ. Gabapentin. Epilepsia 1995;36[Suppl]:S73–S86.

75. Priebe MM, Sherwood AM, Graves DE, et al. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997;35:171–175.

76. Dunevsky A, Perel A. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998;77:451–454.

77. Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open label trial. Neurology 1996;47:939–944.

78. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306–1310.

79. Burbaud P, Wiart L, Dubos JL, et al. A randomized, double-blind placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265–269.

80. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989;65:208–210.

81. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990;28:512–515.

82. Cosgrove AP, Lorry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36(5):386–396.

83. Koman LA, Mooney JF III, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double- blind trial. J. Pediatr Orthop 1994;14(3):299–303.

84. Segal JL, Pathak MS, Hernandez JP, et al. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19(6):713–723.

85. Segal JL, Hayes K, Brunnemann SR, et al. Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. J Clin Pharmacol 2000;40:402–409.

86. Potter PJ, Hayes KC, Hsieh JT, et al. Sustained improvements in neurological function in spinal cord patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998;36(3):147–155.

87. Segal JL, Brunnemann SR. 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans. J Spinal Cord Med 1998;21(3):200–204.

88. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, cross-over study in eight patients. J Neurotrauma 1993;10(1):1–18.

89. Donovan WH, Halter JA, Graves DE, et al. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000;38(1):7–15.

90. Bruckner C, Heinemann U. Effects of standard anti- convulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res 2000;859(1):15–20.

91. Bever CT Jr, Anderson PA, Leslie J, et al. Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996;47(6):1457–1462.

92. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517–1521.

93. Lee KC, Carson L, Kinnin E, Patterson V. The Ash- worth Scale: a reliable and reproducible method of measuring spasticity. J Neurol Rehabil 1989;3:205–209.

94. Ochs G, Struppler A, Meyerson BA, et al. Intrathecal baclofen for long-term treatment of spasticity: a multi- centre study. J Neurol Neurosurg Psychiatry 1989;52:933–939.

95. Albright AL, Barron WB, Fasick MP, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2475–2477.

96. Dralle D, Muller H, Zierski J, Klug N. Intrathecal baclofen for spasticity. Lancet 1985;8462:1003.

97. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years’ experience. J Neurosurg 1992;77:236–240.

98. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11:77–83.

99. Wiens HD. Spasticity in children with cerebral palsy: a retrospective review of the effects of intrathecal baclofen. Issues Compr Pediatr Nurs 1998;21(1):49–61.

100. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265:1418–1422.

101. Gilmartin R, Bruce D, Storrs B, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71–77.

102. Grande MA, Chacon J, Trujillo J, et al. Intrathecal perfusion pump with baclofen in generalized dystonia. Rev Neurol 2000;30(2):138–140.

103. Albright AL, Barry MJ, Shultz B. Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J Neurosurg 1998;88(1):73–76.

104. Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil 1999;80(1):13–19.

105. Nance PW, Schryvers OI, Schmidt BJ, et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admission. Can J Neurol Sci 1995;22:122–129.

106. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner 1964;192:540–542.

107. Nanninga JB, Frost F, Penn R. Effect of intrathecal baclofen on bladder and sphincter function. J Urol 1989;142:101–105.

108. Siegfried J, Rea GL. Intrathecal application of drugs for muscle hypertonus. Scand J Rehab Med 1988;17[Suppl]:145–148.

109. Terrance CF, Fromm GH, Roussan MS. Baclofen: its effects on seizure frequency. Arch Neurol 1983;40:28–29.

110. Badr GG, Matousek M, Frederiksen PK. A quantitative EEG analysis of the effects of baclofen on man. Neuropsychobiology 1983;10:13–18.

111. Coletti A, Mandelli A, Minoli G, Tredici G. Post- anoxic action myoclonus (Lance-Adams syndrome) treated with levodopa and GABA-ergic drugs. J Neurol 1980;223:67–70.

112. Pedersen E, Grynderup V, Kissmeyer-Nielsen F, et al. Familial progressive myoclonic epilepsy. J Neurol 1982;53:305–320.

113. Rosen I, Fehling C, Sedgwick M, Elmqvist D. Focal reflex epilepsy with myoclonus: electrophysiological investigation and therapeutic implications. Electroencephalogr Clin Neurophysiol 1977;42:95–106.

114. Cohen SL, Raines A, Panagakos J, Armitage P. Phenytoin and chlorpromazine in the treatment of spasticity. Arch Neurol 1980;37:360–364.

115. Stark RJ. Spasticity due to phenytoin toxicity. Med J Aust 1979;1(5):156.

116. Holden KR, Titus MO. The effect of tiababine on spasticity in children with intractable epilepsy: a pilot study. Pediatr Neurol 1999;21(4):728–730.

117. Hill DR, Bowery N. H-1 Baclofen and H-1-GABA bind to bicuculline-insensitive GABA(B) sites in rat brain. Nature 1981;290:149–152.

118. Sandyk R. Treatment of writer’s cramp with sodium valproate and baclofen. S Afr Med J 1983;63:702–703.

119. Fodstad H, Ljunggren BCA. Baclofen and carbamazepine in supraspinal spasticity. J R Soc Med 1991;84:100–101.

120. Bittencourt PR, Silvado CE. Oxcarbazepine, GP47779, and spasticity. Lancet 1985;2(8456):676.

121. Bittencourt PR. Oxcarbazepine and spasticity: further observations. Arq Neuropsiquiatr 1988;46(4):382–384.

122. Cendrowski W, Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol 1977;16:257–262.

123. McCarty CS, Kiefer EJ. Thoracic lumbar and sacral spinal cordectomy. Proc Staff Meet Mayo Clin 1949;24:108.

124. Bischof W. Die longitudinale myelotomie. Zentralbl Neurochir 1951;11:79–88.

125. Bischof W. Zur dorsalen longitudinalen myelotomie. Zentralbl Neurochir 1967;28:123–126.

126. Laitinen L, Nilsson S, Fugl-Myer AR. Selective posterior rhizotomy for treatment of spasticity. J Neurosurg 1983;58:895–899.

127. Moyes PD. Longitudinal myelotomy for spasticity. J Neurosurg 1969;31:615–619.

128. Smyth MD, Peacock WJ. The surgical treatment of spasticity. Muscle Nerve 2000;23:153–163.

129. Sindou M, Misfud JJ, Boisson D, Goutelle A. Selective posterior rhizotomy in the dorsal root entry zone for treatment of hyperspasticity and pain in the hemiplegic upper limb. Neurosurgery 1986;18:587–595.

130. Mertens P, Sindou M. Microsurgical DREZotomy for the treatment of spasticity of the lower limbs. Neurochirurgie 1998;44:209–218.

131. Balasubramaniam V, Kanaka TS, Ramanujam PB. Stereotaxic surgery for cerebral palsy. J Neurosurg 1974;40:577–582.

132. Broggi G, Angelini L, Bono R. Long-term results of stereotaxic thalamotomy for cerebral palsy. Neurosurgery 1983;12:195–202.

133. Gornall P, Hitchcock E, Kirkland IS. Stereotaxic neurosurgery in the management of cerebral palsy. Dev Med Child Neurol 1975;17:279–286.

134. Guidetti B, Fraioli B. Neurosurgical treatment of spasticity and dyskinesias. Acta Neurochir Suppl (Wien) 1977;24:27–39.

135. Siegfried J, Lazorthes Y, Broggi G, et al. La neurochirurgie fonctionnelle de l'infirmite motrice cerebrale. Neurochirurgie 1985;31:1–118.

136. Cooper IS, Riklan M, Amin I, et al. Chronic cerebellar stimulation in cerebral palsy. Neurology 1976;26:744–753.

137. Davis R, Schulman J, Delehanty A. Cerebellar stimulation for cerebral palsy—five-year study. Acta Neurochir Suppl (Wien) 1980;30:317–332.

138. Schulman JH, Davis R, Nanes M. Cerebellar stimulation for spastic cerebral palsy: preliminary report. Ongoing double blind study. Pacing Clin Electrophysiol 1987;10:226–231.

139. Nomura Y, Fukuuchi A, Iwade M, et al. A case of spasticity following spinal cord injury improved by epidural spinal cord stimulation. Masui 1995;44:732–734.

140. Gottlieb GL, Myklebust BM, Stefosk D. Evaluation of cervical stimulation for chronic treatment of spasticity. Neurology 1985;35:699–704.

141. Hugenholtz H, Humphreys P, McIntyre WM, et al. Cervical spinal cord stimulation for spasticity in cerebral palsy. Neurosurgery 1988;22:707–714.

142. Harris GF, Millar EA, Hemmy DC, Lochner RC. Neuroelectric stimulation in cerebral palsy: long-term quantitative assessment. Stereotact Funct Neurosurg 1993;61(2):49–59.

143. Bensman AS, Szegho M. Cerebellar electrical stimulation: a critique. Arch Phys Med Rehabil 1978;59:485–487.

144. Ivan LP, Ventureyra EC, Wiely J, et al. Chronic cerebellar stimulation in cerebellar palsy. Surg Neurol 1981;15:81–84.

145. Ivan LP, Ventureyra EC. Chronic cerebellar in cerebral palsy. Childs Brain 1982;9:121–125.

146. Barolat G, Singh-Sahni K, Staas WE Jr, et al. Epidural spinal cord stimulation in the management of spasms in spinal cord injury: a prospective study. Stereotact Funct Neurosurg 1995;64(3):153–164.

147. Midha M, Schmitt JK. Epidural spinal cord stimulation for the control of spasticity in spinal cord injury patients lacks long-term efficacy and is not cost-effective. Spinal Cord 1998;36(3):190–192.

148. Galanda M, Hovath S. Different effect of chronic electrical stimulation of the region of the superior cerebellar peduncle and the nucleus ventralis intermedius of the thalamus in the treatment of movement disorders. Stereotact Funct Neurosurg 1997;69:116–120.

149. Galanda M, Mistina L, Zoltan O. Behavioural responses to cerebral stimulation in cerebral palsy. Acta Neurochir Suppl (Wien) 1989;46:37–38.

150. Abbe R. Resection of the posterior roots of spinal nerves to relieve pain, pain reflex, and spastic paralysis—Dana’s operation. Med Record (NY) 1911;79: 377–381.

151. Sherrington CS. Decerebrate rigidity and reflex coordination of movements. J Physiol (Lond) 1898;22:319–337.

152. Foerster O. On the indications and results of the excision of posterior spinal nerve roots in man. Surg Gynecol Obstet 1913;16:463–474.

153. Geos C, Ouknine G, Vlahovitch B, Frerebeau P. La radicotomie selective posterieure dans le traitement neurochirurgical de l’hypertonie pyramidale. Neurochirurgie 1967;13:505–518.

154. Privat JM, Benezech J, Frerebeau P, Gros C. Sectorial posterior rhizotomy, a new technique of surgical treatment for spasticity. Acta Neurochir (Wien) 1976;35:181–195.

155. Fasano VA, Broggi G, Barolat-Romana G, Sguazzi A. Surgical treatment of spasticity in cerebral palsy. Childs Brain 1978;4:289–305.

156. Baker LD, Hill LM. Foot alignment in the cerebral palsy patient. J Bone Joint Surg 1964;40:577–582.

157. Banks HH, Green WT. The correction of equinus deformity in cerebral palsy. J Bone Joint Surg 1958;40:1359–1379.

158. McCouch GP, Deering ID, Ling TH. Location of receptors for tonic neck reflexes. J Neurophysiol 1951;14:191–195.

159. Kottke FJ. Modification of athetosis by denervation of the tonic neck reflexes. Dev Med Child Neurol 1981;15:81–84.

160. Benedetti A, Carbonin C, Colombo F. Extended posterior cervical rhizotomy for severe spastic syndromes with dyskinesias. Appl Neurophysiol 1977; 40:41–47.

161. Peacock WJ, Staudt LA. Central and peripheral neuro- surgical management of cerebral palsy. Semin Orthop 1987;4:229–235.

162. Fraioli B, Nicci F, Baldassarree L. Bilateral cervical rhizotomy: effects on dystonia and athetosis, on respiration and other autonomic functions. Appl Neurophysiol 1977;40:26–40.

163. Munro D. The rehabilitation of patients totally paralyzed below the waist: anterior rhizotomy of spastic paraplegia. N Engl J Med 1945;233:453–461.

164. Garland DE, Thompson R, Waters R. Musculocutaneous neurectomy for spastic elbow flexion in nonfunctional upper extremities in adults. J Bone Joint Surg 1981;63A:767–772.

165. Purohit AK, Raju BS, Kumar KS, Mallikarjun KD. Selective musculocutaneous fasciculotomy for spastic elbow in cerebral palsy: a preliminary study. Acta Neurochir (Wien) 1998;140:473–478.

166. Decq P, Filipetti P, Feve A. Peripheral selective neurectomy of the brachial plexus collateral branches for treatment of the spastic shoulder: anatomical study and clinical results in five patients. J Neurosurg 1997;86:648–653.

167. Feve A, Decq P, Filipetti P. Physiological effects of selective tibial neurotomy on lower limb spasticity. J Neurol Neurosurg Psychiatry 1997;63:575–578.

168. Caillet F, Mertens P, Rabaseda S, Boisson D. The development of gait in the hemiplegic patient after selective tibial neurotomy. Neurochirurgie 1998;4:183–191.

169. Berard C, Sindou M, Berard J, Carrier H. Selective neurotomy of the tibial nerve in the spastic hemiplegic child: an explanation of the recurrence. J Pediatr Orthop 1998;7B:66–70.

170. Helweg-Larsen J, Jacobsen E. Treatment of spasticity in cerebral palsy by means of phenol nerve block of peripheral nerves. Dan Med Bull 1969;16:20–25.

171. Spira R. Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol 1971;13:164–173.

172. Carpenter EB. Role of nerve blocks in the foot and ankle in cerebral palsy. Foot Ankle 1983;4:164–166.

173. Garland DE, Lucie RS, Waters RL. Current uses of open phenol nerve block for adult acquired spasticity. Clin Orthop 1982;165:271–222.

From: Bassi V, Kita M, Feldman DS, and Devinsky O. Spasticity. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;231–247.
With permission from Elsevier (www.elsevier.com).
Reviewed May 2004 by Steven C. Schachter, MD, epilepsy.com Editorial Board.